HRAS Codon 13 Missense
Associated Genetic Biomarkers
HRAS Codon 13 Missense is present in 0.12% of AACR GENIE cases, with bladder urothelial carcinoma, salivary duct carcinoma, and cutaneous melanoma having the greatest prevalence .
HRAS Codon 13 Missense serves as an inclusion eligibility criterion in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial that contains HRAS Codon 13 Missense as an inclusion criterion, 1 is phase 2 (1 open).
Trials with HRAS Codon 13 Missense in the inclusion eligibility criteria most commonly target thyroid gland carcinoma .
Trametinib is the most frequent therapy in trials with HRAS Codon 13 Missense as an inclusion criteria .
Significance of HRAS Codon 13 Missense in Diseases
Thyroid Gland Carcinoma +
HRAS is altered in 4.91% of thyroid gland carcinoma patients .
HRAS Codon 13 Missense is an inclusion criterion in 1 clinical trial for thyroid gland carcinoma, of which 1 is open and 0 are closed. Of the trial that contains HRAS Codon 13 Missense and thyroid gland carcinoma as inclusion criteria, 1 is phase 2 (1 open) .
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. Liu X, Wu C, Li C, and Boerwinkle E. dbNSFP v3.0: A one-stop database of functional predictions and annotations for human nonsynonymous and splice site SNVs. Human Mutation. 2015;37:235-241.
Liu X, Jian X, and Boerwinkle E. dbNSFP: A lightweight database of human nonsynonymous SNPs and their functional predictions. Human Mutation. 2011;32:894-899.
4. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.